ACADIA Pharmaceuticals Inc. (ACAD) — Financial statements
Income statement, balance sheet, and cash flow for ACADIA Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,072↑11.9% | 958↑31.8% | 726↑40.4% | 517↑6.8% | 484 | |
| Cost of Revenue | 89↑8.7% | 82↑79.0% | 46↑349.8% | 10↓46.9% | 19 | |
| Gross Profit | 983↑12.2% | 876↑28.7% | 681↑34.2% | 507↑9.0% | 465 | |
| Operating Expenses | ||||||
| R&D Expenses | 329↑8.4% | 303↓13.8% | 352↓2.8% | 362↑51.0% | 239 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 393 | 0.00↓100.0% | 396 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 9 | 0.00 | 0.00 | |
| SG&A Expenses | 549↑12.4% | 488↑21.4% | 402↑9.0% | 369↓6.8% | 396 | |
| Other Expenses | 0.00↑100.0% | -147 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 878↑36.0% | 645↓14.4% | 754↑3.2% | 731↑15.0% | 635 | |
| Total Costs & Expenses | 967↑33.0% | 727↓9.1% | 800↑8.0% | 741↑13.2% | 655 | |
| Operating Results | ||||||
| Operating Income | 105↓54.6% | 231↑414.5% | -73↑67.2% | -224↓31.2% | -170 | |
| Depreciation & Amortization | 0.00↓100.0% | 16↑186.1% | 6↑174.0% | 2↓39.4% | 3 | |
| EBITDA | 139↑38.7% | 100↑247.7% | -68↑69.4% | -222↓32.6% | -167 | |
| EBIT | 139↑64.8% | 84↑214.9% | -73↑67.2% | -224↓31.2% | -170 | |
| Interest & Other Income | ||||||
| Net Interest Income | 32↑24.6% | 25↑47.7% | 17↑160.7% | 7↑1018.4% | 0.59 | |
| Interest Income | 32↑24.6% | 25↑47.7% | 17↑160.7% | 7↑1018.4% | 0.59 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -34↓123.3% | 147 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 34↑25.0% | 27↑22.1% | 22↑120.1% | 10↑247.7% | 3 | |
| Income Before Tax | 139↓46.2% | 258↑605.7% | -51↑76.1% | -213↓27.4% | -168 | |
| Income Tax Expense | -252↓897.2% | 32↑208.5% | 10↑305.0% | 3↑621.1% | 0.35 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 391↑72.7% | 226↑469.5% | -61↑71.6% | -216↓28.7% | -168 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 391↑72.7% | 226↑469.5% | -61↑71.6% | -216↓28.7% | -168 | |
| Bottom-Line Net Income | 391↑72.7% | 226↑469.5% | -61↑71.6% | -216↓28.7% | -168 | |
| EPS (Basic) | 2.32↑69.3% | 1.37↑470.3% | -0.37↑72.4% | -1.34↓27.6% | -1.05 | |
| EPS (Diluted) | 2.29↑68.4% | 1.36↑467.6% | -0.37↑72.4% | -1.34↓27.6% | -1.05 | |
| Weighted Average Shares | 169↑2.2% | 166↑1.2% | 164↑1.3% | 162↑0.7% | 160 | |
| Weighted Average Diluted Shares | 171↑3.0% | 166↑1.6% | 164↑1.3% | 162↑0.7% | 160 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.